RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aptose Biosciences Stock

Aptose Biosciences Net Income 2024

Aptose Biosciences Net Income

-79.8 M USD

Ticker

APS.TO

ISIN

CA03835T2002

WKN

A12C5N

In 2024, Aptose Biosciences's profit amounted to -79.8 M USD, a 55.83% increase from the -51.21 M USD profit recorded in the previous year.

The Aptose Biosciences Net Income history

YEARNET INCOME (undefined USD)
2030e54.61
2029e98.11
2028e47.68
2027e8.25
2026e-32.33
2025e-40.45
2024e-79.8
2023-51.21
2022-41.82
2021-65.35
2020-55.24
2019-26.28
2018-28.87
2017-11.66
2016-14.24
2015-11.71
2014-9.9
2013-5.54
2012-4.62
2011-4.96
20105.01
2009-7.66
2008-6.25
2007-8.48
2006-15.26
2005-17.53
2004-22.58

Aptose Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Aptose Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Aptose Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Aptose Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Aptose Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Aptose Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Aptose Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Aptose Biosciences’s growth potential.

Aptose Biosciences Revenue, EBIT and net profit per share

DateAptose Biosciences RevenueAptose Biosciences EBITAptose Biosciences Net Income
2030e600.98 M undefined500.98 M undefined54.61 M undefined
2029e433.12 M undefined403.32 M undefined98.11 M undefined
2028e300.54 M undefined107.28 M undefined47.68 M undefined
2027e166.49 M undefined16.82 M undefined8.25 M undefined
2026e0 undefined-25.09 M undefined-32.33 M undefined
2025e0 undefined-30.59 M undefined-40.45 M undefined
2024e0 undefined-58.8 M undefined-79.8 M undefined
20230 undefined-52.36 M undefined-51.21 M undefined
20220 undefined-42.6 M undefined-41.82 M undefined
20210 undefined-65.45 M undefined-65.35 M undefined
20200 undefined-55.77 M undefined-55.24 M undefined
20190 undefined-26.86 M undefined-26.28 M undefined
20180 undefined-29.11 M undefined-28.87 M undefined
20170 undefined-11.83 M undefined-11.66 M undefined
20160 undefined-14.27 M undefined-14.24 M undefined
20150 undefined-12.86 M undefined-11.71 M undefined
20140 undefined-8.67 M undefined-9.9 M undefined
20130 undefined-5.57 M undefined-5.54 M undefined
20120 undefined-4.6 M undefined-4.62 M undefined
20110 undefined-4.91 M undefined-4.96 M undefined
2010123,200 undefined-5.28 M undefined5.01 M undefined
2009159,200 undefined-6.2 M undefined-7.66 M undefined
200842,400 undefined-10.82 M undefined-6.25 M undefined
200794,200 undefined-7.18 M undefined-8.48 M undefined
200622,200 undefined-14.15 M undefined-15.26 M undefined
20054,800 undefined-17.37 M undefined-17.53 M undefined
2004453,200 undefined-23.51 M undefined-22.58 M undefined

Aptose Biosciences stock margins

The Aptose Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aptose Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aptose Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Aptose Biosciences's sales revenue. A higher gross margin percentage indicates that the Aptose Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Aptose Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Aptose Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Aptose Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Aptose Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Aptose Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Aptose Biosciences Margin History

Aptose Biosciences Gross marginAptose Biosciences Profit marginAptose Biosciences EBIT marginAptose Biosciences Profit margin
2030e100 %83.36 %9.09 %
2029e100 %93.12 %22.65 %
2028e100 %35.7 %15.87 %
2027e100 %10.1 %4.95 %
2026e100 %0 %0 %
2025e100 %0 %0 %
2024e100 %0 %0 %
2023100 %0 %0 %
2022100 %0 %0 %
2021100 %0 %0 %
2020100 %0 %0 %
2019100 %0 %0 %
2018100 %0 %0 %
2017100 %0 %0 %
2016100 %0 %0 %
2015100 %0 %0 %
2014100 %0 %0 %
2013100 %0 %0 %
2012100 %0 %0 %
2011100 %0 %0 %
2010100 %-4,283.04 %4,068.59 %
2009100 %-3,893.97 %-4,814.51 %
200895.28 %-25,515.1 %-14,732.08 %
200785.03 %-7,620.17 %-9,004.78 %
200688.29 %-63,752.7 %-68,734.24 %
200583.33 %-361,785.4 %-365,129.13 %
200495.39 %-5,186.92 %-4,983.16 %

Aptose Biosciences Aktienanalyse

What does Aptose Biosciences do?

The company Aptose Biosciences was founded in 1986 and is based in Toronto, Canada. It specializes in the discovery and development of drugs for the treatment of cancer and other serious diseases. History: Aptose Biosciences was originally known as Lorus Therapeutics, specializing in the development of antibodies and peptides. However, in 2007, the company changed its name to Aptose Biosciences and focused on cancer drugs. In 2011, Aptose obtained the license for CG'806, a promising cancer therapy that was later introduced into clinical development in 2017. Business model: Aptose Biosciences' business model is based on the discovery and development of drugs for the treatment of cancer and other serious diseases. The company works closely with leading scientists and researchers to identify and develop new and innovative therapies that have the potential to improve patients' lives. Aptose Biosciences also collaborates with pharmaceutical companies worldwide to advance the development and commercialization of its products. Divisions: Aptose Biosciences focuses on two main areas: the discovery and development of cancer therapies and the discovery of biomarkers that can be used in the diagnosis and treatment of cancer. The cancer therapy division of Aptose focuses on the development of drugs that can target the causes of cancer. The company utilizes innovative technologies to identify and develop new and promising drug candidates that have the potential to improve the lives of patients with various types of cancer. The biomarker division of Aptose focuses on the discovery of biomarkers that can be useful in the diagnosis and treatment of cancer. The company collaborates closely with other companies and research institutions to identify and validate new biomarkers that can contribute to the improvement of cancer diagnosis and treatment. Products: Aptose Biosciences currently offers several cancer drugs that are in different stages of clinical development. The most promising product of Aptose Biosciences is CG'806, which is currently in phase 1 clinical development. CG'806 is a first-in-class cancer drug that has the potential to combat multiple types of cancer. Other products of Aptose Biosciences include APTO-253, which is used for the treatment of AML (acute myeloid leukemia), and APTO-267, which is used for the treatment of CLL (chronic lymphocytic leukemia). Additionally, Aptose Biosciences is working on the development of other cancer therapies that are in various stages of development. Conclusion: Aptose Biosciences is a leading biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other serious diseases. The company has several promising cancer therapies in different stages of clinical development, as well as a promising biomarker division specializing in cancer diagnosis and treatment. With a strong focus on innovation and collaboration, Aptose Biosciences remains an important player in cancer research and therapy. Aptose Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Aptose Biosciences's Profit Margins

The profit margins of Aptose Biosciences represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Aptose Biosciences's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Aptose Biosciences's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Aptose Biosciences's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Aptose Biosciences’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Aptose Biosciences stock

How much profit has Aptose Biosciences made this year?

Aptose Biosciences has made -79.8 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 55.83% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Aptose Biosciences publish its earnings?

Aptose Biosciences publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Aptose Biosciences?

The profits of Aptose Biosciences are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Aptose Biosciences?

You can learn more about the earnings of Aptose Biosciences by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Aptose Biosciences pay?

Over the past 12 months, Aptose Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aptose Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Aptose Biosciences?

The current dividend yield of Aptose Biosciences is .

When does Aptose Biosciences pay dividends?

Aptose Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aptose Biosciences?

Aptose Biosciences paid dividends every year for the past 0 years.

What is the dividend of Aptose Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aptose Biosciences located?

Aptose Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aptose Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aptose Biosciences from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did Aptose Biosciences pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of Aptose Biosciences in the year 2023?

In the year 2023, Aptose Biosciences distributed 0 USD as dividends.

In which currency does Aptose Biosciences pay out the dividend?

The dividends of Aptose Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Aptose Biosciences stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Aptose Biosciences

Our stock analysis for Aptose Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aptose Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.